March 3, 2026Open Access

Real-world experience with belimumab-based triple therapy in proliferative lupus nephritis: data from the BEL-SPAIN Registry

Key Points

High renal response rates were observed with belimumab-based triple therapy, indicating its effectiveness.
Extrarenal response rates also showed substantial improvement, emphasizing comprehensive treatment benefits.
Data analysis from the BEL-SPAIN Registry highlights real-world efficacy and safety in clinical practice.
Effects demonstrate potential for increased GC-sparing outcomes and treat-to-target strategies in therapy.

Abstract

BEL-based triple therapy is effective and safe in proliferative LN, achieving high renal and extrarenal response rates, substantial GC-sparing and treat-to-target outcomes in real-world practice.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Paola Vidal-Montal

Bellvitge University Hospital

Aina Fabregat

Bellvitge University Hospital

Irene Altabás-González

Universidad de Las Palmas de Gran Canaria

Journals

Lupus Science & Medicine

SHILAP Revista de lepidopterología

Actions

Institutions

Universitat de Barcelona

Hospital Clínic de Barcelona

Hospital de Sant Pau

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Real-world experience with belimumab-based triple therapy in proliferative lupus nephritis: data from the BEL-SPAIN Registry

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Also consider